Search
HCW 2026: BlossomHill IPO'd last month to tackle precision oncology, with a Scientific Founder / CEO who already has a hall of fame record in the space - Jean Cui walks us through her programs
She highlights the company's next generation EGFR, which is in the clinic and reported early stage data at World Lung today, and she describes her goal with the company's Pan-KRAS inhibitor, which is still preclinical. Coverage brought to you by
Sep 15
BlossomHill Therapeutics raises a $100M series B to work on precision medicine small molecules
Scientific founder, president & CEO J. Jean Cui describes her scientific approach of working to solve resistance mutations.
Mar 1, 2024
.png){kind=logo}